The Unreasonable Effectiveness of Lifestyle
It wasn’t quite like the dream where you’re standing in front of an audience and suddenly realize you’re not wearing pants, but at a recent... Read More
Biotech Leaders Get It
About David Shaywitz
David Shaywitz, MD PhD is a contributing writer for Timmerman Report.
Focus: the transformational opportunities and implementation challenges presented by emerging technologies in healthcare, biomedical discovery, and biopharmaceutical development, from NGS and cell therapies to digital biomarkers and the meaningful application of AI. Co-author (with Lisa Suennen): Tech Tonics: Can Passionate Entrepreneurs Heal Healthcare With Technology? (Hyperink Press, 2014).
Background: Drawing on two decades of biopharma experience, Dr. Shaywitz applies deep R&D expertise to guide and invest in the strategic adoption of emerging technologies to accelerate the discovery, development and delivery of impactful new therapies for patients.
Dr. Shaywitz’s career has centered on advancing pharmaceutical research by appreciating the transformative potential of nascent technologies while also recognizing the unique challenges of incorporating these technologies into complex biopharma environments. He has particular expertise in guiding promising technology and technology innovators through the complex scientific, cultural, and organizational landscape of biopharma.In addition to his writing for TR, Dr. Shaywitz is also a frequent speaker and writer on topics at the intersection of medicine, science, and innovation, and contributes book reviews regularly to the Wall Street Journal.
Dr. Shaywitz serves as a lecturer in the Department of Biomedical Informatics at Harvard Medical School, is an advisor to the MS/MBA Biotechnology Life Science Program at Harvard GSAS/HBS, and is an Adjunct Scholar at the American Enterprise Institute.
Latest Contributions
Agency: The Motivational Currency of Health
Last night I offered some remarks at February’s Boston Health Innovation Night, a monthly gathering of innovators, entrepreneurs, and investors in Boston’s extraordinary biomedical ecosystem,... Read More
Can We Ride the GenAI Wave Without Getting Subsumed by It?
“There are decades where nothing happens; and there are weeks where decades happen,” said Lenin, probably never. It’s also a remarkably apt characterization of the... Read More
To Improve Health, Design for Agency
Agency — the conviction I can shape my future — is a vital driver of human health and human potential. It is also the factor... Read More
A New Book on GLP-1’s Contested Scientific Roots and Complex Cultural Impact — Plus Further Reading
In this weekend’s Wall Street Journal, I review Off the Scales, a fascinating new book by Reuters journalist Aimee Donnellan about the discovery and development... Read More
Why Patients – And Many Innovative Doctors – Are Pursuing Health Outside the System
Our current system of delivering care is awful from the perspective of seemingly every stakeholder. It frustrates, enrages, saddens, and depletes patients and physicians alike.... Read More
The Outsized Significance of A New Study of AI in Diabetes Prevention
A lifestyle intervention delivered by AI was found to be as effective as validated traditional interventions delivered by trained experts in a carefully conducted implementation... Read More
The Biology of Belonging: Social Connection Meets Geroscience
Digital health, fitness, and longevity platforms have focused on the constant measurement and relentless optimization of biometric parameters, an often-valuable effort but one that has... Read More